EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives
Jiabao Hou(Zhengzhou University), Qiming Wang(Hunan Cancer Hospital), Jing Han(University of Augsburg), Sen Yang, Li Wang(First Hospital of Jiaxing), Zhen He(Hunan Normal University), Zhe Zhang(Peking University), Shuxiang Ma(Zhengzhou University), Lidan Hao(Zhengzhou University), Hanqiong Zhou(Zhengzhou University), Hongle Li(Shanghai Jiao Tong University)
Cited by 58
Related Papers
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial
|Journal of Thoracic Oncology|2021|311
MEK inhibitors for the treatment of non-small cell lung cancer
|Journal of Hematology & Oncology|2021|300
Radiotherapy remodels the tumor microenvironment for enhancing immunotherapeutic sensitivity
|Cell Death and Disease|2023|130